Regeneron Pharmaceuticals Inc vs Western Digital Corp — how do they compare? Regeneron Pharmaceuticals Inc trades at $652 (market cap $70.79B), while Western Digital Corp trades at $564.95 (market cap $189.02B). The key difference: Western Digital Corp is far larger — about 2.7× Regeneron Pharmaceuticals Inc's market cap, and Regeneron Pharmaceuticals Inc pays the higher dividend (0.56%). Which is the better fit depends on your goals.
| REGN | WDC | |
|---|---|---|
Market Cap | $70.79B | $189.02B |
Sector | Health | Technology |
52-Week High | $812.27 | $746.23 |
52-Week Low | $545.46 | $67.06 |
Enterprise Value | $64.74B | $187.36B |
Dividend Yield | 0.56% | 0.11% |
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.
The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.
Western Digital (WDC) trades at $548.07, up 14.85% over 24 hours, reflecting strong momentum in memory stocks. The stock exhibits a bearish technical signal but has beaten earnings estimates for three consecutive quarters. Key financials show robust profitability with a net income margin of 55.07% and ROE of 37.73%. Recent news highlights WDC's position in the AI-driven memory and storage rebound, with institutional buying activity noted.
Outlook remains positive given analyst consensus and AI-driven demand, though valuation multiples are elevated. Risks include market volatility and competitive pressures. The consensus price target of $619.07 suggests potential upside, supported by strong institutional sentiment and fundamental improvements.
Trailing returns across standard periods
Latest headlines on both assets
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →Western Digital is a vertically integrated supplier of data storage solutions, spanning both hard disk drives and solid-state drives. In the HDD market it forms a practical duopoly with Seagate, and it is the largest global producer of NAND flash chips for SSDs in a joint venture with competitor Kioxia.
Read more on WDC →